Efavirenz + Emtricitabine + Tdf Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 600/200/300 mg
Reference Brands: Atripla(US/EU)
Category: Anti Viral
Atripla Tablets (Efavirenz 600 mg, Emtricitabine 200 mg, Tenofovir 300 mg) offer a once-daily, fixed-dose HIV treatment. Available via PharmaB2B platforms from WHO-GMP and USFDA-approved suppliers, Atripla is ideal for bulk procurement, tenders, and HIV programs. Ensure reliable supply from trusted global manufacturers. Efavirenz + Emtricitabine + TDF is available in Tablet and strengths such as 600/200/300 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Efavirenz + Emtricitabine + TDF is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Efavirenz + Emtricitabine + TDF can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Atripla Tablets combine Efavirenz (600 mg), Emtricitabine (200 mg), and Tenofovir Disoproxil Fumarate (300 mg) in a once-daily, fixed-dose antiretroviral therapy for HIV-1 infection. Widely recommended in global HIV treatment guidelines, Atripla simplifies adherence and improves patient outcomes. On PharmaB2B platforms, global pharmaceutical buyers, NGOs, and procurement agencies can source WHO-GMP and USFDA-approved Atripla formulations from trusted manufacturers. Ideal for tender supply, HIV programs, and institutional purchases, Atripla is available for bulk export at competitive prices. Partner with verified suppliers on PharmaB2B to ensure timely, compliant delivery of high-quality antiretrovirals essential for public health programs.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Efavirenz, emtricitabine, and tenofovir disoproxil fumarate (TDF) are used together as a single-tablet regimen to treat HIV-1 infection. This combination helps lower viral load, improve immune function, and prevent HIV progression when taken regularly.
It is made from three antiretroviral agents: efavirenz (a non-nucleoside reverse transcriptase inhibitor), emtricitabine (an NRTI), and tenofovir disoproxil fumarate (an NRTI). Together they block HIV replication at multiple stages.
The common trade name is Atripla.
Atripla is co-developed by Gilead Sciences and Bristol-Myers Squibb, with several generic manufacturers producing it globally.
The generic name is efavirenz, emtricitabine, and tenofovir disoproxil fumarate.
The primary brand name is Atripla.
It is manufactured in approved facilities in the USA, Europe, and India, depending on whether it is the innovator or a generic version.
Related Products
Maraviroc
Strength:
150 mg, 300 mg, 20 mg
Form: Tablets / Oral solution
Reference Brands: Selzentry (USA), Celsentri (EU)
View Details
Raltegravir
Strength:
100mg, 400 mg, 600mg
Form: Tablets
Reference Brands: Isentress (USA/EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
